Information Provided By: 
Fly News Breaks for October 10, 2016
CLDX
Oct 10, 2016 | 07:35 EDT
Brean Capital analyst Jason Wittes noted Celldex released Phase ll melanoma data. Although the data was not enough for an accelerated approval pathway, it still was encouraging, said Wittes, who noted the company said they would continue to explore the drug. Wittes maintained his Buy rating and $16 price target on Celldex shares.
News For CLDX From the Last 2 Days
There are no results for your query CLDX
